A share price of Inovio Pharmaceuticals Inc [INO] is currently trading at $2.75, up 1.48%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The INO shares have gain 11.79% over the last week, with a monthly amount glided 85.81%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Inovio Pharmaceuticals Inc [NASDAQ: INO] stock has seen the most recent analyst activity on July 09, 2025, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $5. Previously, Stephens started tracking the stock with Overweight rating on May 14, 2024, and set its price target to $20. On January 25, 2024, upgrade upgraded it’s rating to Outperform but maintained its price target of $4 on the stock. Maxim Group downgraded its rating to a Hold. BofA Securities downgraded its rating to a Underperform but $2 remained the price target by the analyst firm on November 01, 2022. In a note dated May 11, 2022, Oppenheimer downgraded an Perform rating on this stock.
Inovio Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $1.30 and $7.00. Currently, Wall Street analysts expect the stock to reach $22.67 within the next 12 months. Inovio Pharmaceuticals Inc [NASDAQ: INO] shares were valued at $2.75 at the most recent close of the market. An investor can expect a potential return of 724.36% based on the average INO price forecast.
Analyzing the INO fundamentals
Trailing Twelve Months sales for Inovio Pharmaceuticals Inc [NASDAQ:INO] were 0.18M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at -11.52% with Operating Profit Margin at -525.69%, Pretax Profit Margin comes in at -138359.6%, and Net Profit Margin reading is -246264.2%. To continue investigating profitability, this company’s Return on Assets is posted at -658.01, Equity is -809.7 and Total Capital is -2.62. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.37.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.64 points at the first support level, and at 2.54 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.82, and for the 2nd resistance point, it is at 2.90.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Inovio Pharmaceuticals Inc [NASDAQ:INO] is 1.66. In addition, the Quick Ratio stands at 1.66 and the Cash Ratio stands at 0.77. Considering the valuation of this stock, the price to sales ratio is 811.92, the price to book ratio is 3.54.
